Skip to comments.FDA approves brain stem cell transplant
Posted on 10/20/2005 7:38:34 PM PDT by aposiopetic
SAN FRANCISCO --Federal regulators on Thursday approved what would be the first transplant of fetal stem cells into human brains, a procedure that if successful could open the door to treating a host of neural disorders.
The Food and Drug Administration said that doctors at Stanford University Medical Center can begin the testing on six children afflicted with Batten disease, a degenerative malady that renders its young victims blind, speechless and paralyzed before it kills them.
An internal Stanford review board must still approve the test, a process that could take weeks.
- snip -
What's more, some of the brain cells to be implanted will be derived from aborted fetuses, which Caplan also said raised ethical concerns for some.
Stem Cells Inc., the Palo Alto, Calif. biotechnology company developing the Batten disease treatment, said it receives it fetal tissue from a nonprofit California foundation that also collects tissue from miscarriages and other surgical processes. Stem Cells chief executive Martin McGlynn declined to name the foundation.
(Excerpt) Read more at boston.com ...
For what it's worth, this is not approval in the sense that a product is approved for marketing to address a particular indication. Rather, it would seem that the sponsor's Investigational New Drug application has not been put on clinical hold, at least for now.
Surgical processes that result in less than a 50% survival rate, it seems.
Did you notice the link below the article, to a company that sells fetal stem cell treatments? ( http://www.medra.com/ ) Run by an MD in Malibu, CA; but you have to get the "treatment" in the Dominican Republic. Already $$$ to be made...
Well, on most occasions one of the two (or more) patients walks away, but I agree with what you are saying, that the other one has had no "choice."
I missed that.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|Date of Report (Date of Earliest Event Reported):||October 19, 2005|
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|of incorporation)||File Number)||Identification No.)|
|3155 Porter Drive, Palo Alto, California||94304|
(Address of principal executive offices)
|Registrants telephone number, including area code:||650.475.3100|
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On October 20, 2005, StemCells, Inc. announced that that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase I safety and preliminary efficacy trial of the Company’s proprietary human neural stem cell product, HuCNS-SC™, to treat Batten disease. A copy of the press release is attached hereto as Exhibit 99.1.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|October 20, 2005||By:|| Martin McGlynn
|Name: Martin McGlynn|
|Title: President and CEO|
Chief Financial Officer
(650) 475-3100 ext 105
|Schwartz Communications, Inc.
(781) 684-0770 or (415) 512-0770
STEMCELLS, INC. RECEIVES FDA CLEARANCE TO INITIATE PHASE I CLINICAL TRIAL OF NEURAL STEM CELLS TO
TREAT BATTEN DISEASE
First-Ever FDA-Approved Trial to Transplant Human Neural Stem Cells
PALO ALTO, Calif., (October 20, 2005) StemCells, Inc. (NASDAQ: STEM) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase I safety and preliminary efficacy trial of the Companys proprietary human neural stem cell product -HuCNS-SC- to treat Batten disease. Batten disease is a rare, fatal genetic disorder that affects the central nervous system of children. This is the first-ever FDA-approved clinical trial to use a purified composition of human neural stem cells as a potential therapeutic agent in humans.
It is truly gratifying that the FDA is permitting this clinical trial to go forward, said Martin McGlynn, President and Chief Executive Officer of StemCells, Inc. This development is a noteworthy milestone not only for our Company, but also for the entire field of stem cell therapeutics. Most importantly, it offers hope to the children and families afflicted by this disease for which there is now no cure, and to the clinicians who are seeking a treatment for their patients.
Physicians have been essentially helpless to assist children suffering from Batten disease. This trial opens the possibility that in the future, we may be able to provide relief to our patients and their families from one of the cruelest and most devastating diseases, said Dr. Gregory Enns, Assistant Professor of Pediatrics and Director of the Biochemical Genetics Program, Stanford University School of Medicine.
Dr. Stephen Huhn, Chief of Pediatric Neurosurgery at Packard Childrens Hospital at Stanford University, added, Years of laboratory research are now moving into the clinic, and it is my fervent hope that the proposed neurosurgical intervention will provide some relief for the children with this terrible disease and for the families who care for them. I look forward to participating in the first trial of neural stem cell transplantation for a rare and fatal brain disorder in children that has no effective known treatment.
About the Clinical Trial
The proposed Phase I trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC for the treatment of infantile and late-infantile neuronal ceroid lipofuscinosis (NCL), the most severe forms of a group of disorders commonly referred to as Batten disease. In addition to measuring the safety of HuCNS-SC, the trial will provide initial data on HuCNS-SCs ability to affect the progression of the disease. Potential patients will be tested for eligibility and then evaluated for baseline disease status prior to transplantation of HuCNS-SC. Children enrolled in the study will be evaluated with standardized measures of development, cognition, behavior and language for one year following HuCNS-SC transplantation. The Company is committed to following the effects of this therapy long-term, so trial patients will also be asked to commit to a four-year follow-up study. The Company plans to seek Institutional Review Board (IRB) approval from a number of leading medical institutions, including the Stanford University School of Medicine.
About Batten Disease
Batten disease is named after the British pediatrician who first described the juvenile form of NCL in 1903. It is also known as Spielmeyer-Vogt-Sjogren-Batten disease. The name is now commonly used to encompass all three forms of NCLinfantile, late infantile and juvenile onset. All forms have the same basic causelack of a lysosomal enzymeand have a similar progression and outcome. The different forms of NCL have traditionally been classified by age of onset. Now with genetic testing, the disease is more precisely classifiable in terms of mutations in the specific enzyme causing the disease. Children with Batten disease suffer seizures, progressive loss of motor skills, sight and mental capacity, eventually becoming blind, bedridden and unable to communicate. Today, Batten disease is always fatal.
In two subtypes of NCL, infantile and late infantile, the disorder is brought on by inherited mutations in the CLN1 gene, which codes for palmitoyl-protein thioesterase 1 (PPT1) or in the CLN2 gene, which codes for tripeptidyl peptidase I (TPP-I). The consequence of these mutations is either a defective or a missing enzyme that leads to accumulation of lipofuscin-like fluorescent inclusions in various cell types. Presumably, these non-degraded lysosomal substrates accumulate to the point where they interfere with normal cellular and tissue function and ultimately lead to the pathological manifestations of the disease. One way to treat the disease is to provide the brain with a replacement source of functional enzyme that can be taken up by the enzyme-deficient cells.
StemCells human central nervous system stem cells (HuCNS-SC) are a somatic cell therapy product consisting of neural cells prepared under controlled conditions. Neural stem cells, a rare subset of brain cells, are isolated from the human fetal brain, purified, propagated, and tested; they are then frozen in cell banks from which HuCNS-SC doses can be prepared.
A property of HuCNS-SC is that they spread throughout the brain and produce both of the lysosomal enzymes missing in the subtypes of Batten disease being studied in the clinical trial. When HuCNS-SC is transplanted into the brain of a preclinical mouse model developed to mimic the human form of Infantile NCL, the enzyme level increases and continues to do so over time after the transplant. Thus, placement of HuCNS-SC in appropriate places in the brain provides the prospect of long-term delivery of the missing enzyme. The production of both enzymes by HuCNS-SC provides a scientific justification for enzyme replacement and cellular rescue in these two subtypes of Batten disease.
About StemCells, Inc.
StemCells, Inc. is a development stage biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver and pancreas. The Companys stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury. StemCells is the first company to directly identify and isolate human neural stem cells from normal brain tissue. These stem cells are expandable into cell banks for therapeutic use, which demonstrates the feasibility of using normal, non-genetically modified cells as cell-based therapies. StemCells is the only publicly traded company solely focused on stem cell research and development and has more than 40 U.S. and 100 non-U.S. patents, as well as more than 100 patent applications pending worldwide. Further information about the Company is available on its web site at: www.stemcellsinc.com.
Apart from statements of historical facts, the text of this press release constitutes forward-looking statements regarding, among other things, the future business operations of StemCells, Inc. (the Company) and its ability to conduct clinical trials as well as its research and product development efforts. The forward-looking statements speak only as of the date of this news release. StemCells does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect managements current views and are based on certain assumptions that may or may not ultimately prove valid. The Companys actual results may vary materially from those contemplated in the forward-looking statements due to risks and uncertainties to which the Company is subject, including uncertainty regarding whether a suitable site for the clinical trial will be identified, whether the required Institutional Review Board approval will be obtained for any site, and whether results obtained in the animal model of Infantile NCL will be able to be translated into treatment for human conditions; uncertainty as to whether the FDA will permit the Company to continue clinical testing in the Batten disease trial or in future clinical trials of proposed therapies for other diseases or conditions despite the novel and unproven nature of the Companys technology; uncertainties regarding the Companys ability to obtain the capital resources needed to continue its current research and development operations and to conduct the research, preclinical development and clinical trials necessary for regulatory approvals; uncertainty regarding the validity and enforceability of the Companys patents; uncertainty as to whether HuCNS-SC and any products that may be generated in the future in the Companys stem cell programs will prove safe and clinically effective and not cause tumors or other side effects; uncertainty as to whether the Company will achieve revenues from product sales or become profitable; and other factors that are described in Exhibit 99 to the Companys Annual Report on Form 10-K titled Cautionary Factors Relevant to Forward-Looking Statements.
Thanks for the megaping.
|Industries | Top All-time Donors | Donor Lookup | PACs | Soft Money | Lobbyists|
|Industries | Top All-time Donors | Donor Lookup | PACs | Soft Money | Lobbyists|
Looks like the interests of the business were served by donations to the likes of Clinton, Harkin, Kerry, Leahy and -- what a surprise! < /sarc > -- Specter.
True. But we (or at least I) also thought gene therapy was on the fast track before the tragic death of Jesse Gelsinger.
Hmmm. Why don't they try it with umbilical cord blood stem cells as well, just to see if it works?
Alas, I am guessing that the principals see absolutely no moral distinction between the use of umbilical cord blood stem cells and the use of (aborted) fetal stem cells.
and a third for good measure
bump for later
and a bump for now just to alert the FReading public
yes, a bump to the top
Weissman, et. al., are using already doomed babies and babies with a deadly disease for the same reason - and to advance that reason - that they give to use frozen embryos: "they are/were going to die, anyway."
It is never right to to evil to good. We all know this, and it is the very basic knowledge that drives the choice of this particular experiment: it's a test case to prove that people in the US will give in, as they did on IVF, abortion, and "assisted suicide," out of concern for visible victims.
Way back in 2003, we knew that human umbilical cord cells functioned to repair spinal cord injury. Weissman knew.
I agree with aposiopetic's irritation with the lack of concern and uproar.
How much will we put up with before we say "Enough!"
The use of fetal cells from abortions is purely unnecessary.
From this mongth's Annals of the New York Academy of Sciences, more on the promise of HUCB stem cells in repair of neural disorders:
Human umbilical cord blood (HUCB) is now considered a valuable source for stem cell-based therapies. HUCB cells are enriched for stem cells that have the potential to initiate and maintain tissue repair. This potential is especially attractive in neural diseases for which no current cure is available. Furthermore, HUCB cells are easily available and less immunogenic compared to other sources for stem cell therapy such as bone marrow. Accordingly, the number of cord blood transplants has doubled in the last year alone, especially in the pediatric population. The therapeutic potential of HUCB cells may be attributed to inherent ability of stem cell populations to replace damaged tissues. Alternatively, various cell types within the graft may promote neural repair by delivering neural protection and secretion of neurotrophic factors. In this review, we evaluate the preclinical studies in which HUCB was applied for treatment of neurodegenerative diseases and for traumatic and ischemic brain damage. We discuss how transplantation of HUCB cells affects these disorders and we present recent clinical studies with promising outcome.
I'm appalled. I can't believe that the FDA, which is supposed to have been hijacked by conservatives, is approving an embryonic stem cell experiment when alternative therapies have not been exhausted. Thanks for the link.
I should have pinged you to my #28 or #29 with info about umbilical cord and bone marrow cells.
"The use of fetal cells from abortions is purely unnecessary." Doctor, the state of California has decided to fund ESCR to the tune of billions in tax dollars. It is vital that the related 'treatments' maintain the dehumanized state of the unborn. So there is 'necessity' in this evil, for the profiteers to come.
Thanks for the ping. I'm always fascinated with the medical breakthroughs using umbilical cord stem cells.
Not to necessarily plug my blog, but I have many more links in yesterday's post concerning this story.
There is no excuse for using fetal cells. We know how horribly they failed in adult Parkinson's Disease. Those experiments even resulted in sham brain surgeries on other patients - all "approved." And now, these babies will have holes drilled in their heads and the brain cells of other babies inserted.
thanks for finding and posting that 'follow the money' info.